|
Bioatla, Inc. (BCAB) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
BioAtla, Inc. (BCAB) Bundle
Entdecken Sie das finanzielle Potenzial von Bioatla, Inc. (BCAB) mit unserem benutzerfreundlichen DCF-Taschenrechner! Geben Sie Ihre Annahmen in Bezug auf Wachstum, Margen und Ausgaben ein, um den inneren Wert von Bioatla, Inc. (BCAB) zu berechnen und Ihre Anlagestrategie zu verbessern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.2 | .4 | .3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -91.75 | -41.72 | -100 | 0 | -58.37 | -58.37 | -58.37 | -58.37 | -58.37 |
| EBITDA | -27.4 | -33.5 | -94.1 | -106.5 | -122.2 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -526.25 | -7798.6 | -37627.6 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .9 | 1.0 | 1.3 | 1.2 | 1.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 16.54 | 234.97 | 532 | 100 | 100 | 83.31 | 83.31 | 83.31 | 83.31 | 83.31 |
| EBIT | -28.2 | -34.5 | -95.4 | -107.7 | -123.5 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -542.79 | -8033.57 | -38159.6 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 3.7 | 238.6 | 245.0 | 215.5 | 111.5 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 0 | 100 | 100 | 40 | 40 | 40 | 40 | 40 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 100 | 100 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 5.1 | 2.5 | 1.2 | 4.2 | 3.8 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 98.83 | 572.49 | 471.6 | 100 | 100 | 99.77 | 99.77 | 99.77 | 99.77 | 99.77 |
| Capital Expenditure | -1.5 | -.6 | -.9 | -.3 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -29.02 | -137.53 | -369.6 | 100 | 100 | -45.8 | -45.8 | -45.8 | -45.8 | -45.8 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -29.7 | -35.8 | -95.4 | -106.5 | -123.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -25.2 | -38.1 | -96.3 | -102.5 | -122.8 | -3.8 | .0 | .0 | .0 | .0 |
| WACC, % | 8.61 | 8.61 | 8.61 | 8.6 | 8.61 | 8.61 | 8.61 | 8.61 | 8.61 | 8.61 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -109 | |||||||||
| Equity Value | 105 | |||||||||
| Diluted Shares Outstanding, MM | 48 | |||||||||
| Equity Value Per Share | 2.21 |
What You Will Receive
- Authentic BioAtla Data: Preloaded financial metrics – from revenue to EBIT – based on actual and forecasted figures for BioAtla, Inc. (BCAB).
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates to suit your analysis.
- Immediate Valuation Adjustments: Automatic recalculations to evaluate the effects of changes on BioAtla’s fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth projections.
- Efficient and Precise: Avoid the hassle of building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Customizable Clinical Data Inputs: Adjust vital parameters such as trial success rates, projected revenue, and R&D expenses.
- Instant DCF Analysis: Automatically computes intrinsic value, NPV, and other financial metrics in real-time.
- High-Precision Valuation: Leverages BioAtla's (BCAB) actual financial data for accurate valuation results.
- Effortless Scenario Testing: Evaluate various assumptions and analyze different outcomes with ease.
- Efficiency Booster: Streamlines the valuation process, removing the need for intricate model creation from scratch.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review BioAtla, Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions regarding BioAtla, Inc. (BCAB).
Why Choose This Calculator for BioAtla, Inc. (BCAB)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Modify parameters effortlessly to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to BioAtla's valuation as you tweak inputs.
- Preloaded Data: Comes with BioAtla’s actual financial information for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Evaluate BioAtla’s (BCAB) intrinsic value to support informed investment choices.
- CFOs: Utilize a high-caliber DCF model for precise financial reporting and analysis.
- Consultants: Seamlessly customize the template for client valuation reports.
- Entrepreneurs: Acquire knowledge on financial modeling techniques employed by leading biotech firms.
- Educators: Employ it as a resource to illustrate valuation strategies in the classroom.
What the Template Contains
- Pre-Filled DCF Model: BioAtla’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate BioAtla’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.